Uncategorized

HAMILTON, ONTARIO — Researchers studying how different aspects of music influence the body turned a live electronic music concert into a lab study. By introducing levels of bass over speakers that were too low to hear and monitoring the crowd’s movements, scientists found that people danced 11.8 percent more when the very low frequency bass was present. The study appears Monday

PISCATAWAY, NEW JERSEY — Capping a year of highly successful new product and program introductions,  Signia took the stage before 150+ attendees at its 2022 National Sales Meeting from October 10 – 13 at JW Marriott Orlando, Grande Lakes and pledged to continue the momentum in 2023 by providing partners and patients with a ‘Brilliant Fit’ that goes beyond innovative

JACKSONVILLE, FLORIDA — Birdsong Hearing Benefits™ has announced a partnership with Convey Health Solutions to serve as its preferred hearing benefits manager. Convey, based in Ft. Lauderdale, Fla., is a leading provider of technology and services to support healthcare organizations and individuals in the Medicare markets. Through this partnership Birdsong will deliver hearing benefit services as a third-party administrator. These services

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022. “This past quarter has been one of momentum and execution. With the completion of enrollment for the Phase 2b

PISCATAWAY, NEW JERSEY – Signia today announced that it is holding its second virtual Signia Student University (SSU) event, featuring several in-depth and interactive sessions that deliver key insights and knowledge for audiology doctorate program students. The free program will kick-off with a live welcome event on December 6th at 6:00 pm ET led by Mike O’Neil, President of Signia

BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, has announced the submission of Clinical Trial Applications (CTAs) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the Spanish Agency of Medicines and Medical Devices (AEMPS) for a Phase

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin

HAMILTON, BERMUDA — Altamira Therapeutics Ltd. (formerly known as Auris Medical), a company dedicated to developing therapeutics that address important unmet medical needs, has announced that it has entered into an agreement regarding the sale of certain of its legacy assets comprised of its inner ear therapeutics research and development programs and a license to use its RNA delivery technology

PARIS, FRANCE — M. Charles Liberman, PhD, whose research forever changed the way experts understand  the underlying causes of hearing loss, has been awarded the Scientific Grand Prize from the France-based La Fondation Pour l’Audition. The award is one of the highest honors given in hearing science and was presented to Dr. Liberman in a ceremony in Paris, France, on

New York — Yes Hearing, a leading provider of affordable, accessible, and convenient hearing technology and audiology care, today announced that it closed a $10M Series A financing round. The investment was led by Blue Heron Capital with participation from Primetime Partners, Ensemble Innovation Ventures, Maccabee Ventures & Gaingels. “Hearing care is a critical component of healthy aging. The unique challenge with hearing loss is that we